Newsfeeds Archive - Page 5 of 6

1 minute read

Aridis Pharmaceuticals Provides AR 501 Phase 2 Trial Update

January 17, 5:31 PM

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its

ARDS

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

December 29, 5:31 PM

Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 53.2% to $0.31 during Thursday’s after-market session. Today’s trading volume…

APTX

1 minute read

Aridis Pharmaceuticals To Discuss Topline Data From Phase 3 Study Of AR-301 During Corporate Update Call On January 25

By Benzinga Newsdesk

December 28, 9:35 AM

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference

ARDS

1 minute read

Aridis Pharmaceuticals Files Prospectus Related To Resale By Certain Selling Stockholder Of Up To 7.2M Shares Of Common Stock

By Michael Horton

December 7, 5:56 PM

-SEC Filing

ARDS

1 minute read

News

Aridis Signs Exclusive Terms To Secure Worldwide Commercial Licenses For Pan-Ebola And Pan-Marburg Monoclonal Antibody Programs From Mapp Biopharmaceutical

By Benzinga Newsdesk

December 5, 8:05 AM

The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval

ARDS

3 minute read

Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket

By Lisa Levin

September 27, 6:29 AM

Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for Vurolenatide in short bowel syndrome.

AKBA

5 minute read

Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday

By Lisa Levin

September 27, 5:15 AM

Gainers

ACMR

1 minute read

Aridis Pharmaceuticals Announces Proposed Public Offering Of Common Stock; No Size Disclosed

By Benzinga Newsdesk

September 26, 3:39 PM

LOS GATOS, Calif., Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

ARDS

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

August 22, 2:30 PM

AGLE

5 minute read

Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

August 22, 1:02 PM

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares surged 78% to $2.2399 as the stock continued to see momentum despite the company last week announcing it is not aware of any developments that would explain the recent surge.

ADES